WO2002048372A3 - Target enzymes - Google Patents

Target enzymes

Info

Publication number
WO2002048372A3
WO2002048372A3 PCT/US2001/048528 US0148528W WO0248372A3 WO 2002048372 A3 WO2002048372 A3 WO 2002048372A3 US 0148528 W US0148528 W US 0148528W WO 0248372 A3 WO0248372 A3 WO 0248372A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted enzymes
target enzymes
enzymes
bind
methods
Prior art date
Application number
PCT/US2001/048528
Other languages
French (fr)
Other versions
WO2002048372A2 (en
Inventor
Yiyou Chen
Anthony G Day
David A Estell
Christopher J Murray
Scott D Power
Volker Schellenberger
Original Assignee
Genencor Int
Yiyou Chen
Anthony G Day
David A Estell
Christopher J Murray
Scott D Power
Volker Schellenberger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor Int, Yiyou Chen, Anthony G Day, David A Estell, Christopher J Murray, Scott D Power, Volker Schellenberger filed Critical Genencor Int
Priority to CA002431858A priority Critical patent/CA2431858A1/en
Priority to AU2002230889A priority patent/AU2002230889A1/en
Priority to EP01991146A priority patent/EP1341907A2/en
Publication of WO2002048372A2 publication Critical patent/WO2002048372A2/en
Publication of WO2002048372A3 publication Critical patent/WO2002048372A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes.
PCT/US2001/048528 2000-12-14 2001-12-14 Target enzymes WO2002048372A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002431858A CA2431858A1 (en) 2000-12-14 2001-12-14 Targeted enzymes comprising substrate recognition sites and target binding sites
AU2002230889A AU2002230889A1 (en) 2000-12-14 2001-12-14 Target enzymes
EP01991146A EP1341907A2 (en) 2000-12-14 2001-12-14 Target enzymes

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60/000,000 2000-09-15
US25577400P 2000-12-14 2000-12-14
US60/255,774 2000-12-14
US27960901P 2001-03-28 2001-03-28
US60/279,609 2001-03-28

Publications (2)

Publication Number Publication Date
WO2002048372A2 WO2002048372A2 (en) 2002-06-20
WO2002048372A3 true WO2002048372A3 (en) 2003-05-30

Family

ID=26944947

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/048528 WO2002048372A2 (en) 2000-12-14 2001-12-14 Target enzymes
PCT/US2001/048529 WO2002047717A2 (en) 2000-12-14 2001-12-14 Targeted enzyme prodrug therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048529 WO2002047717A2 (en) 2000-12-14 2001-12-14 Targeted enzyme prodrug therapy

Country Status (2)

Country Link
AU (2) AU2002230889A1 (en)
WO (2) WO2002048372A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1700119T3 (en) * 2003-12-18 2010-06-07 Genencor Int Beta-lactamase CD4 + T cell epitopes
EP1735350B1 (en) 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept
ITBG20120050A1 (en) * 2012-10-29 2013-01-28 Michele Mutti FUSION PROTEIN WITH PROTEASIC ACTIVITY AND SPECIFICITY OF ANTIBODIES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079479A2 (en) * 2000-04-14 2001-10-25 Genencor International, Inc. Methods for selective targeting

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079479A2 (en) * 2000-04-14 2001-10-25 Genencor International, Inc. Methods for selective targeting

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DEFEO-JONES D ET AL: "A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 6, no. 11, November 2000 (2000-11-01), pages 1248 - 1252, XP002208104, ISSN: 1078-8956 *
DEONARAIN M P ET AL: "TARGETING ENZYMES FOR CANCER THERAPY: OLD ENZYMES IN NEW ROLES", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 70, no. 5, 1 November 1994 (1994-11-01), pages 786 - 794, XP000654784, ISSN: 0007-0920 *
FRANKEL A E ET AL: "Targeted toxins.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES FEB 2000, vol. 6, no. 2, February 2000 (2000-02-01), pages 326 - 334, XP002223271, ISSN: 1078-0432 *
NICULESCU-DUVAZ ION ET AL: "Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).", ANTI-CANCER DRUG DESIGN, vol. 14, no. 6, December 1999 (1999-12-01), pages 517 - 538, XP002223270, ISSN: 0266-9536 *
SIEMERS NATHAN O ET AL: "Modifying the specificity and activity of the Enterobacter cloacae P99 beta-lactamase by mutagenesis within an M13 phage vector.", BIOCHEMISTRY, vol. 35, no. 7, 1996, pages 2104 - 2111, XP002223269, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
WO2002047717A9 (en) 2003-05-30
WO2002048372A2 (en) 2002-06-20
WO2002047717A2 (en) 2002-06-20
AU2002230889A1 (en) 2002-06-24
AU2002230890A1 (en) 2002-06-24
WO2002047717A3 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2002017914A3 (en) Fused pyrrolocarbazoles against inflammation
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2001083554A3 (en) Anti-inflammatory compounds and uses thereof
WO2001062280A3 (en) Lipase-containing composition and methods of use thereof
WO2004048551A3 (en) Target for therapy of cognitive impairment
WO1998051662A3 (en) Compounds and methods for the inhibition of the expression of vcam-1
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
WO2002030353A3 (en) NF-λB INHIBITORS
WO1999058674A3 (en) Method of inhibiting osteoclast activity
WO2003057145A3 (en) SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
WO2003105753A3 (en) Targeted enzymes and methods of making and using targeted enzymes.
WO2002030941A3 (en) Topoisomerase inhibitors
WO2002018954A3 (en) Inhibition of cmv infection and dissemination
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
WO2002024695A3 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU7216498A (en) Inhibitors of the urokinase receptor
WO2002048372A3 (en) Target enzymes
WO2004060878A3 (en) Inhibitors of phosphatases
WO2003077874A3 (en) Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004026892A3 (en) Fragmentation of dna
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2431858

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002550087

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001991146

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001991146

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)